Reduction of Postherpetic Neuralgia in Herpes Zoster

Part of paid clinical trials in Houston, Texas.

Sponsor
Center for Clinical Studies, Texas
Study ID
NCT01250561
Status
Completed

Conditions

  • Herpes Zoster
  • Post-herpetic Neuralgia

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Gabapentin — DRUG
    gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks
  • Valacyclovir — DRUG
    valacyclovir 1000mg three-times daily x 7 days

Study Details

The addition of gabapentin therapy to standard antiviral treatment with valacyclovir in acute herpes zoster patients will decrease the incidence of post-herpetic neuralgia.

Key Dates

Start date
Feb 28, 2002
Status verified
Nov 2010
Primary completion
Oct 31, 2007
Completion
Oct 31, 2007

Study Design

Enrollment
133 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Proportion of patients with zoster pain at 6 months

Locations (1)

FacilityCityStateZIPSite coordinators
Center for Clinical StudiesHoustonTexas77030-

Find similar trials in Houston, TX

By research site
Center for Clinical Studies· Houston, TX

Related Studies